Lung cancer symptoms and pulse oximetry in the prognostic assessment of patients with lung cancer by Martins, Sandro J et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Lung cancer symptoms and pulse oximetry in the prognostic 
assessment of patients with lung cancer
Sandro J Martins*1,3, Nelson Ho1, Sueli O Cavamura2, Cecilia M Harada2, 
Crystina A Yamamoto3 and Teresa Y Takagaki1
Address: 1Pulmonary Division, University of São Paulo Medical School, Av. Dr. Arnaldo 455, 01246-903 São Paulo, Brazil, 2Psychology Section, 
Hospital das Clínicas, University of São Paulo Medical School, Av. Dr. Arnaldo 455, 01246-903 São Paulo, Brazil and 3Oncology Unit, Hospital 
Santa Izabel, Pca Almeida Couto 500, 40050-410 Salvador, Brazil
Email: Sandro J Martins* - sjmartins@yahoo.com; Nelson Ho - ho_nelson@hotmail.com; Sueli O Cavamura - sueliokubo@hotmail.com; 
Cecilia M Harada - plctg@yahoo.com; Crystina A Yamamoto - crysaoki@yahoo.com; Teresa Y Takagaki - t.takagaki@hcnet.usp.br
* Corresponding author    
Abstract
Background: Medical oncologists continue to use performance status as a proxy for quality of life
(QOL) measures, as completion of QOL instruments is perceived as time consuming, may measure
aspects of QOL not affected by cancer therapy, and interpretation may be unclear. The pulse
oximeter is widely used in clinical practice to predict cardiopulmonary morbidity after lung
resection in cancer patients, but little is known on its role outside the surgical setting. We evaluated
whether the Lung Cancer Symptom Scale and pulse oximetry may contribute to the evaluation of
lung cancer patients who received standard anticancer therapy.
Methods: We enrolled forty-one consecutive, newly diagnosed, patients with locally advanced or
metastatic lung cancer in this study. We developed a survival model with the variables gender, age,
histology, clinical stage, Karnofsky performance status, wasting, LCSS symptom scores, average
symptom burden index, and pulse oximetry (SpO2).
Results: Patient and observer-rated scores were correlated, except for the fatigue subscale. The
median SpO2 was 95% (range: 86 to 98), was unrelated to symptom scores, and was weakly
correlated with observer cough scores. In a multivariate survival model, SpO2 > 90% and patient
scores on the LCSS appetite and fatigue subscales were independent predictors of survival.
Conclusion: LCSS fatigue and appetite rating, and pulse oximetry should be studied further as
prognostic factors in lung cancer patients.
Background
The symptoms of lung cancer are a burden to patients, and
a major detriment to their quality of life (QoL) and ability
to function. Several different instruments have been
developed to assess QoL of lung cancer patients, with rec-
ognized reliability and validity [1,2], yet their use is not
widespread. Medical oncologists continue to use perform-
ance status as a proxy for QOL measures, as completion of
QOL instruments is perceived as time consuming, may
measure aspects of QOL not affected by cancer therapy,
and interpretation may be unclear [3]. Whether formal
QoL evaluation can improve patient care and disease
Published: 06 July 2005
BMC Cancer 2005, 5:72 doi:10.1186/1471-2407-5-72
Received: 09 July 2004
Accepted: 06 July 2005
This article is available from: http://www.biomedcentral.com/1471-2407/5/72
© 2005 Martins et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2005, 5:72 http://www.biomedcentral.com/1471-2407/5/72
Page 2 of 6
(page number not for citation purposes)
outcome, perhaps through helping medical reasoning, by
adding information to other well-known prognostic fac-
tors is a matter of active research.
The Lung Cancer Symptom Scale (LCSS) is a disease-and
site-specific instrument developed in 1985 by Patricia
Hollen and colleagues at the Memorial Sloan-Kettering
Cancer Center, primarily to assess quality of life for indi-
viduals with lung cancer, both in its physical and func-
tional aspects. It is focused on six clinically important
lung cancer symptoms that are likely to affect patients'
physical and functional status. Although it lacks detail in
many QoL domains, such as social, spiritual, and psycho-
logical parameters, the LCSS has demonstrated high inter-
rater reliability, feasibility, reliability, and content validity
when evaluated against the Sickness Impact Profile (appe-
tite), Profiles of Mood States (fatigue), American Thoracic
Society Questionnaire (cough and dyspnea) and the
McGill Pain Questionnaire, and their normative data in
patients with non-small cell lung cancer (NSCLC) has
been published [4-7].
Pulse oximetry is widely used to rapidly monitor arterial
oxygen saturation (SpO2) [8]. It has many of the charac-
teristics of an ideal monitoring technique: portability,
non-invasiveness, ease of use (calibration is not required)
and the capability for continuous on-line monitoring of
SpO2. SpO2 measurement may be particularly useful in
the care patients with advanced lung cancer, leading to
early detection and appropriate management of hypox-
emia, a condition likely to occur in this clinical setting [9].
In this study, we evaluate the prognostic value of baseline
LCSS scores and pulse oximetry in a cohort of ambulatory
patients, with advanced lung cancer, receiving standard
medical therapy.
Method
Design
This was an observational cohort study. Consecutive out-
patients with advanced or metastatic lung cancer who
attended the pulmonology division of the Hospital das
Clínicas of the University of São Paulo, Brazil, were
invited to participate. All procedures were conducted in
accordance with the ethical standards of the World Medi-
cal Association Declaration of Helsinki and Institutional
board.
New patients admitted for lung cancer therapy were eligi-
ble if they presented with histological diagnosis of lung
cancer, and locally advanced or metastatic disease extent.
Exclusion criteria included past infection (last month) or
fever (last week); use of supplementary oxygen; and
potential causes for bad signal capture by pulse oximeter:
black skin, nail abnormalities or pigmentation, anemia
(hemoglobin < 10 g/dL), jaundice (bilirubin < 3 mg/dL),
hypotension (systolic bp ≤  90 mmHg), or tachycardia (>
100 bpm) were not included. All patients gave written
signed informed consent before participating.
Lung Cancer Symptom Scale
The LCSS comprises two scales, one for patients and other
for health professionals as observer. The patient scale con-
sists of nine items: six subscales related to major lung can-
cer symptoms (appetite, cough, dyspnea, fatigue,
hemoptysis, and pain), all using 100 mm visual analogue
measurements, and three summation items (activity sta-
tus, symptomatic distress, and overall QoL). The observer
scale is a five-point scale that measures the intensity of
those symptoms (100 = none, 75 = mild, 50 = moderate,
25 = marked, and 0 = severe). The average symptom bur-
den is an ancillary index, obtained as the mean of the six
symptom scales scored separately by patients and the
observer. At study admission, two psychologists explained
all procedures and oriented patients to focus on the past
day information about their symptom perception. A med-
ical oncologist recorded symptom scores using the
observer scale. In this study we used a Portuguese version
of the LCSS developed for Brazil, through a forward and
backward translation process [10].
Pulse oximetry
The attending investigator at the initial medical examina-
tion recorded the mean of three consecutive finger pulse
oximetry measures (Nonim Med Inc; Plymouth, USA),
read at least 20 seconds apart with up to 2% variability, as
the non-invasive estimate of SpO2.
Medical therapy
Chemotherapy, radiotherapy, and supportive measures
were administered on individual basis, and consisted of
non-investigational therapies only. The attending physi-
cian was responsible for indicating the proper therapeutic
modality according to patients' individual characteristics
(comorbidities, clinical status, disease sites, and personal
preferences). All chemotherapy regimens used were
platinum-based.
Data analysis
The following variables were selected for this analysis:
gender, age (years), histology, clinical stage, Karnofsky
performance status (KPS), weight loss (% usual body
weight), symptom subscores (appetite, cough, dyspnea,
fatigue, hemoptysis, and pain), average symptom burden
index, and SpO2.
Due to non-normality constraints, bivariate association
among symptom scores, Karnofsky performance status,
and SpO2 were evaluated by nonparametric statistics
(Spearman's rho). A Cox model was fit by step-wiseBMC Cancer 2005, 5:72 http://www.biomedcentral.com/1471-2407/5/72
Page 3 of 6
(page number not for citation purposes)
procedure, as follows: a global test was performed to show
the simple, unadjusted relationship between factors and
survival, and seven possible explanatory variables were
selected to model building due to its anticipated prognos-
tic value (Wald chi square > 2.7); a stepwise model selec-
tion procedure was used and included explanatory
variables that were significant at the 0.10 level; the likeli-
hood ratio test was used to assess every improvement in
model fitting. We used the SPSS package to perform statis-
tical analysis (version 11.01, SPSS Inc, Chicago, IL).
Results
From Oct 2000 to Apr 2001, forty-one consecutive eligible
new patients with lung cancer were studied. Baseline
demographic and clinical data are presented in Table 1.
Our sample was largely comprised of aged, male,
advanced lung cancer patients. Most patients (83%) had
NSCLC and presented with poor performance status and
weight loss. All patients received initial chemotherapy: in
NSCLC, mitomycin C, vinblastine and cisplatin (61%) or
carboplatin (22%); in small cell lung cancer, cisplatin and
etoposide (17%). Nine patients (22%) received concur-
rent cisplatin radiotherapy (50.4 Gy) consolidation after
four chemotherapy cycles. Median number of LCSS symp-
toms was 5 (range: 1 to 6); fatigue (95%) was the major
presenting symptom, followed by pain (80%), dyspnea
(78%), cough (73%), loss of appetite (68%), and hemop-
tysis (39%). All patients complied with LCSS
administration.
LCSS scores
To compare individual and health professional percep-
tions on symptom distress, the relationship between
patient and observer LCSS scores are showed in Table 2.
We expected significant correlation in all subscales since
they measured the same distress dimension, but we found
disagreement on fatigue evaluation.
Observer-derived average symptom burden index was not
associated with age, histology, clinical stage, and KPS;
except for hemoptysis (p = 0.11) and pain (p = 0.09), it
was correlated with patient-derived subscales: appetite
(rho = 0.33, p = 0.034), fatigue (rho = 0.34, p = 0.031),
cough (rho = 0.54, p = 0.005), and dyspnea (rho = 0.46, p
= 0.002). Patient-derived average symptom burden was
associated with KPS (p = 0.001) and independent of age,
histology, or clinical stage; it was also related to all but
one obsever-derived symptom subscale (pain, p = 0.16):
appetite (rho = 0.39, p = 0.012), fatigue (rho = 0.42, p =
0.006), cough (rho = 0.38, p = 0.014), dyspnea (rho =
0.52, p = 0.0001), and hemoptysis (rho = 0.39, p = 0.013).
Pulse oximetry and LCSS scores
Median SpO2 was 95% (range: 86 to 98); eight patients
(19%) had SpO2 below 90% but were not deemed candi-
dates for domiciliary oxygen therapy. As presented in
Table 3, the SpO2 measurement was unrelated to patient-
derived symptom scores and exhibited only a weak corre-
lation with observer-derived cough scores.
Survival analysis
As of December 2003, thirty-eight patients (93%) had
died and three were lost to follow up. The median survival
was 42 weeks and 36% survived the first year. A multivar-
iate survival model developed from seven possible
explanatory variables is presented in Table 4. SpO2 >
90%, patient-derived scores on the appetite and fatigue
subscales were found to be the only independent prog-
nostic factors in this cohort. Clinical stage retained bor-
derline prognostic value in the final model. Age (p =
0.92), gender (p = 0.79), and Karnofsky's performance
status (p = 0.94) did not behave as independent prognos-
tic factors. Global symptom scores failed to show relevant
prognostic value on univariate tests and were not selected
to the survival modeling.
Table 1: Patient characteristics
Median age (range), in years 63 (34 to 80)
Gender
Male 32 (78%)
Female 9 (22%)
Karnofsky performance status
60 % 3 (7%)
70 % 22 (54%)
80% 11 (27%)
90% 5 (12%)
Clinical Stage
IIIA 7 (17%)
IIIB 12 (29%)
IV 22 (54%)
Histology
Adenocarcinoma 16 (39%)
Squamous cell carcinoma 9 (22%)
Poorly differentiated carcinoma 6 (15%)
Large cell carcinoma 3 (7%)
Small cell carcinoma 7 (17%)
Metastatic sites
Bone 8 (19%)
Addrenal 6 (15%)
Skin 4 (10%)
Lung 3 (7%)
Brain 2 (5%)
Liver 1 (2%)
Wasting 22 (54%)BMC Cancer 2005, 5:72 http://www.biomedcentral.com/1471-2407/5/72
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Discussion
Despite significant advances in cancer medicine, most
physicians still deal with patients suffering from relent-
less, incurable illnesses, and their therapeutic decisions
are often made based on subjective judgments about
patients' QoL. Performance status scales, such as the KPS
introduced in 1949, are widely accepted tools to evaluate
physical functioning of cancer patients. Several recent
studies suggest that a broad QoL evaluation using current
well-structured instruments can provide more detailed
prognostic information. This has been demonstrated for
the Functional Living Index-Cancer [11,12], the European
Organization for Research and Treatment of Cancer
QLC43 form [2,13], and the Functional Assessment of
Cancer Therapy – Lung questionnaire [14,15]. As shown
here, the LCSS and pulse oximetry may be regarded as val-
Table 2: Correlation between patient and observer scores on symptom subscales
Patient scale (mm) * Observer scale (point) * Spearman's rho p-value†
Appetite 31 (19–43) 75 (50–100) -0.52 0.0001
Fatigue 56 (46–65) 50 (0–100) -0.21 N.S.
Cough 29 (19–39) 75 (25–100) -0.71 0.0001
Dyspnea 38 (27–49) 75 (0–100) -0.51 0.001
Pain 44 (32–57) 75 (25–100) -0.36 0.02
Hemoptysis 13 (0–22) 100 (50–100) -0.50 0.001
Global symptom score 35 (28–42) 69 (42–100) -0.57 0.0001
* Median values and range.
† N.S.: Not significant at the 0.05 level (two-tailed)
Table 3: Correlation between pulse oximetry and LCSS subscales
Patient scale Observer scale
Spearman's rho p-value * Spearman's rho p-value
Appetite 0.02 N.S -0.20 N.S.
Fatigue -0.23 N.S -0.19 N.S.
Cough -0.16 N.S -0.33 0.03
Dyspnea 0.07 N.S -0.26 N.S.
Pain -0.13 N.S 0.02 N.S.
Hemoptysis -0.85 N.S -0.20 N.S.
Global symptom score -0.23 N.S. -0.31 0.049
* N.S.: Not significant at the 0.05 level (two-tailed)
Table 4: Survival analysis by Cox regression
β S.E. OR CI 95% p-value
Pulse oximetry (SpO2 < 95%) 1.39 0.63 4.02 1.16–13.85 0.022
Clinical stage (III vs. IV) 0.78 0.43 2.18 0.93–5.06 0.070
Appetite (10 mm) 0.13 0.06 1.14 1.01–1.30 0.041
Fatigue (10 mm) 0.21 0.09 1.23 1.03–1.47 0.019
Overall model: Chi-square = 10.21, p = 0.037
Variables not in the equation: age, gender, and Karnofsky performance statusBMC Cancer 2005, 5:72 http://www.biomedcentral.com/1471-2407/5/72
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uable tools for prognostic assessment in advanced lung
cancer. SpO2 was independent of most LCSS data, and the
combination of SpO2 and LCSS offered independent
prognostic information on overall survival.
A SpO2 below 90% and variation of 10 mm in patient
scores on appetite and fatigue were associated with an
increased hazard of death. Measurement of pulse oxime-
try and completion of the LCSS form were fast and were
not burdensome for the health care staff. The pulse oxime-
ter is widely used in clinical practice to predict cardiopul-
monary morbidity after lung resection in cancer patients
[16], but little is known on its role outside the surgical
setting.
The presence of anorexia and fatigue at initial evaluation
has been associated with shortened overall survival. Loss
of appetite is manifested by 75% of patients with
advanced lung cancer at some point of their disease course
[7], although in cancer centers its assessment eventually
lead to therapeutic interventions in only 60% of the time
[17]. Besides, its true prognostic value may be hidden or
minimized in some studies given the fact that weight loss
is usually the variable of interest. Recently, Hoang et al.
[18] analyzed data from 1,436 patients with stage IV or
IIIB NSCLC included in two randomized phase III Eastern
Cooperative Oncology Group trials and found that loss of
appetite conferred a hazard ratio for death of 1.62.
Fatigue also is a common symptom in patients with can-
cer, and is associated with both physical and psychologi-
cal distress particularly patients with lung [19]. Using
validated specific scales (Cancer Fatigue Scale and Fatigue
Numerical Scale), fatigue that interferes with any daily
activities may be detected in up to 59% of these patients
[20]. Its independent negative impact on survival was
reported in a retrospective study of 1,154 patients with
lung carcinoma [21].
There are shortcomings on the use of SpO2 as a proxy
measure of an estimate of SaO2 in patients with lung can-
cer. The presence of high carboxyhemoglobin values in
heavy smokers could disturb the SpO2 reading by the
pulse oximeter [22]. Many patients with lung cancer have
some degree of chronic obstructive pulmonary disease
(COPD), a condition in which SpO2 may not accurately
represent arterial oxygen saturation [23]. Furthermore, the
small sample size, heterogeneity of therapeutic
approaches, and absence of full data on pulmonary
comorbidity or carboxyhemoglobin values limit generali-
zation of our model. Our four-factors model was fit from
seven variables, from data on 41 patients and 38 events,
and thus could not incorporate further prognostic infor-
mation. In order to achieve reliable estimates of the three
major functions (survival, probability density, and haz-
ard) and their standard errors at each time interval by Cox
regression the minimum recommended sample size
should allow five to ten events per factor in the modeling
set of variables [24,25].
In contrast to the patient's perspective, observers do not
grade symptom distress only but also take into account
the clinical setting related to that problem and discrepan-
cies may rise. In the study presenting the conceptual
model of the LCSS [26], fatigue was found to be the great-
est significant predictor of symptomatic distress in NSCLC
patients throughout therapy. We noticed a lack of correla-
tion between patient and observer fatigue subscales, with
a tendency for physicians to underrate this item. Although
this may be due to misclassification errors on the
categorical differences within the fatigue item by the
observer, a bias towards an underestimation of symptom
intensity by health professionals could not be ruled out.
Discrepancies between observer and patient rated assess-
ments have been reported for other symptom-based
instrument, the Edmonton Symptom Assessment System
[27,28].
To our knowledge, this is the first report suggesting the
existence of a role for pulse oximetry in the assessment of
newly diagnosed lung cancer patients receiving palliative
anticancer therapy. Several issues still need to be clarified,
including the pulse oximetry's performance under influ-
ence of smoking status or the coexistence COPD in lung
cancer patients. Conceivably, its negative impact on prog-
nosis could rely on the relationship of SpO2 with contin-
ued cigarette smoking, a condition associated to therapy
failure and poor survival [29], or low SpO2 would reflect
severity of underlying COPD. Our results add to the evi-
dence that evaluation of lung cancer symptoms improve
assessment of prognosis in the palliative setting, and sup-
port additional larger studies to refine and validate these
findings so that they can be used in daily practice.
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